Lung Cancer Trials Ask AI to find trials
CompletedPhase 3NCT01450761
Official study title

Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone

Study summary

The purpose of the study is to determine whether the addition of Ipilimumab to Etoposide and Platinum therapy will extend the lives of patients with Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) more than Etoposide and Platinum therapy alone.

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedIpilimumab and Placebo matching Ipilimumab

Plus 3 other study approaches.

Who it may be forSmall cell lung cancer (SCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jul 8, 2020 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Phase 3

Interventional

Where is it offered?225 U.S. locations

Locations may change over time.

Who runs it?Bristol-Myers Squibb

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 3
Sponsor
Bristol-Myers Squibb
Interventions being studied
Biological: Ipilimumab; Biological: Placebo matching Ipilimumab; Drug: Etoposide; Drug: Cisplatin; Drug: Carboplatin
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Small cell lung cancer (SCLC)→
Treatment approach
Immunotherapy→Chemotherapy→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
  • Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC)
  • Eastern Cooperative Oncology Group (ECOG) of 0 or 1
Reasons someone may not be able to joinExclusion criteria
  • Prior systemic therapy for lung cancer
  • Symptomatic Central Nervous System (CNS) metastases
  • History of autoimmune disease

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Genesis Cancer CenterHot Springs, Arkansas
  • Sutter Medical CenterAuburn, California
  • UCSD Moores Cancer CenterLa Jolla, California
  • University Of Colorado Cancer CenterAurora, Colorado
  • Florida Cancer Specialists S.Fort Myers, Florida
  • Cancer Specialists, LLCJacksonville, Florida
  • Lake City Cancer CareLake City, Florida
  • Florida Cancer SpecialistsSt. Petersburg, Florida
  • Medical Oncology, LLCAugusta, Georgia
  • Quincy Medical GroupQuincy, Illinois
  • Presence Medical Group Hematology OncologySkokie, Illinois
  • SIU School Of MedicineSpringfield, Illinois

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 8, 2020. Always confirm current availability with the study team.

View original record ↗